Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$223.29 USD
-6.29 (-2.74%)
Updated May 28, 2024 04:00 PM ET
After-Market: $223.32 +0.03 (0.01%) 5:32 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Madrigal (MDGL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$352.85 | $411.00 | $150.00 | 53.69% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for Madrigal comes to $352.85. The forecasts range from a low of $150.00 to a high of $411.00. The average price target represents an increase of 53.69% from the last closing price of $229.58.
Analyst Price Targets (13)
Broker Rating
Madrigal currently has an average brokerage recommendation (ABR) of 1.47 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 1.47 a month ago based on 15 recommendations.
Of the 15 recommendations deriving the current ABR, 12 are Strong Buy, representing 80% of all recommendations. A month ago, Strong Buy represented 80%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 12 | 12 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 1 |
Sell | 1 | 1 | 1 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 1 |
ABR | 1.47 | 1.47 | 1.47 | 1.29 | 1.43 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/7/2024 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
3/20/2024 | Evercore Partners | Liisa A Bayko | Strong Buy | Strong Buy |
3/15/2024 | JMP Securities | Jonathan Wolleben | Strong Buy | Strong Buy |
3/15/2024 | B. Riley Securities | Mayank Mamtani | Strong Sell | Hold |
3/14/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
3/12/2024 | H.C. Wainwright & Co. | Ed Arce | Strong Buy | Strong Buy |
3/8/2024 | Canaccord Genuity | Edward H Nash | Strong Buy | Strong Buy |
2/28/2024 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.47 |
ABR (Last week) | 1.47 |
# of Recs in ABR | 15 |
Average Target Price | $352.85 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 88 of 252 |
Current Quarter EPS Est: | -7.55 |